Flu Vaccines: Quadrivalent Advances In 2015-16 Season; GSK Drops Trivalent
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers begin shipping flu vaccines for upcoming season highlighting tension between picking widely circulating strains and ensuring wide product availability.
You may also be interested in...
FDA Supports FluMist Use, Releases Lots For 2016 Flu Season
Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.